SPS
BCRX icon

Susquehanna Portfolio Strategies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.56M Sell
374,016
-404,505
-52% -$3.14M 0.05% 365
2025
Q4 		$6.07M Buy
+778,521
New +$5.63M 0.09% 281

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Susquehanna Portfolio Strategies's BCRX Position: Q1 2026 in Review

Susquehanna Portfolio Strategies reduced its BioCryst Pharmaceuticals (BCRX) stake by 52% in Q1 2026, selling an estimated $3.14M and leaving 374,016 shares worth $3.56M. The position accounts for 0.05% of the portfolio, ranked #365.

Susquehanna Portfolio Strategies first reported a position in BCRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $6.07M in Q4 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Susquehanna Portfolio Strategies held 374,016 shares of BioCryst Pharmaceuticals worth $3.56M as of Q1 2026.
  • Susquehanna Portfolio Strategies sold 404,505 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $3.14M.
  • BioCryst Pharmaceuticals made up 0.05% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #365 holding.
  • Susquehanna Portfolio Strategies first reported a position in BioCryst Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Susquehanna Portfolio Strategies's BioCryst Pharmaceuticals position peaked at $6.07M in Q4 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.